European Drugmakers Urge EU Pharma Investment
Analysis based on 9 articles · First reported Sep 22, 2026 · Last updated Sep 22, 2026
The letter is a lobbying appeal rather than a binding policy change, so near-term market impact is limited, though it highlights structural competitive pressure on European pharmaceutical capital allocation and could influence future EU healthcare spending and regulatory debates. If EU policymakers respond with faster trial approvals and higher medicine spending, European drugmakers could see improved research pipelines and revenue prospects, while continued inaction would reinforce the relative advantage of US and Chinese competitors.
Chairs of nine European pharmaceutical companies published an open letter on their corporate websites on September 22, 2026, calling on the European Union and its member states to boost investment in the region's drug industry. The signatories were AstraZeneca, GSK plc, Novo Nordisk, Novartis, Roche, Sanofi, Boehringer Ingelheim, Chiesi Farmaceutici and Ipsen. The letter urges faster clinical trials, stronger intellectual property protections and greater fiscal flexibility on healthcare spending, warning that without urgent action strategic sectors such as pharmaceuticals face a slow agony of decline. The chairs stated that roughly 40% of new therapies never reach European patients, that the bloc's share of global drug research and development has fallen to 31% from 43% in 1990, and that its share of commercial clinical trials has halved to 9% over the past decade. They noted Europe spends about 1% of GDP on pharmaceuticals, versus 2% in the United States and 1.8% in China. Amsterdam-based healthcare lawyer Ron Lanton said Europe retains extraordinary scientific capabilities but companies increasingly plan around more aggressive US policies, weighing the entire pathway from clinical trials to reimbursement and patient access when deciding where to allocate capital. The appeal reflects boardroom frustration with European systems and policies that move more slowly than those in the United States and China, which attract billions of dollars more in pharmaceutical investment.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard